Abstract
Within the last decade, methicillin-resistant Staphylococcus aureus (MRSA) has emerged as a frequent cause of purulent skin and soft tissue infections. New therapeutic options are being investigated for these infections. We report an integrated analysis of 2 randomized, controlled studies involving omadacycline, a novel aminomethylcycline, and linezolid for the treatment of acute bacterial skin and skin structure infections (ABSSSI). Omadacycline in Acute Skin and Skin Structure Infections Study 1 (OASIS-1) initiated patients on intravenous omadacycline or linezolid, with the option to transition to an oral formulation after day 3. OASIS-2 was an oral-only study of omadacycline versus linezolid. In total, 691 patients received omadacycline and 689 patients received linezolid. Infection types included wound infection in 46.8% of patients, cellulitis/erysipelas in 30.5%, and major abscess in 22.7%. Pathogens were identified in 73.2% of patients. S. aureus was detected in 74.7% and MRSA in 32.4% of patients in whom a pathogen was identified. Omadacycline was noninferior to linezolid using the Food and Drug Administration primary endpoint of early clinical response (86.2% vs 83.9%; difference 2.3, 95% confidence interval -1.5 to 6....Continue Reading
References
Apr 1, 1985·Statistics in Medicine·O Miettinen, M Nurminen
Jan 9, 1998·Infectious Disease Clinics of North America·M C MarananR S Daum
Sep 2, 2009·Antimicrobial Agents and Chemotherapy·UNKNOWN International Working Group on the Classification of Staphylococcal Cassette Chromosome Elements (IWG-SCC)
Oct 1, 2009·Emerging Infectious Diseases·John EdelsbergGerry Oster
Nov 26, 2011·Journal of Clinical Microbiology·Marcus J ZervosMyoung Kim
Jan 1, 1990·The Canadian Journal of Infectious Diseases = Journal Canadien Des Maladies Infectieuses·C F Carey, L Dall
Jul 5, 2012·JAMA : the Journal of the American Medical Association·Michael L LandrumClinton K Murray
Oct 17, 2012·Paediatric Respiratory Reviews·Sam Mehr, Nicholas Wood
Jan 10, 2013·PloS One·Vanja M DukicMichael Z David
Jun 1, 2013·BMC Infectious Diseases·Gary Thomas RayRoger Baxter
Jul 19, 2013·Future Medicinal Chemistry·Kristin J Labby, Sylvie Garneau-Tsodikova
Nov 28, 2013·Virulence·Robert A Balk
Dec 4, 2013·Antimicrobial Agents and Chemotherapy·A B MaconeS B Levy
Jun 4, 2014·BMC Infectious Diseases·Jose A SuayaLoren G Miller
Jun 29, 2014·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Dennis L Stevens Infectious Diseases Society of America
Jan 22, 2015·The Journal of Emergency Medicine·Charles V PollackDavid Talan
Aug 1, 2015·Hospital Practice·Thomas P LodiseKatherine A Sulham
Nov 26, 2015·PloS One·Keith S KayeKenneth Johnson
Apr 17, 2016·Internal and Emergency Medicine·Marco FalconeFrancesco Violi
Jun 2, 2016·Expert Review of Clinical Pharmacology·Jaime E VerasteguiDavid P Nicolau
Jul 30, 2016·Bioorganic & Medicinal Chemistry·S Ken TanakaStephen Villano
Sep 1, 2017·The Pediatric Infectious Disease Journal·Kristina G HulténSheldon L Kaplan
Jan 31, 2018·Antimicrobial Agents and Chemotherapy·Michael A PfallerRobert K Flamm
Feb 15, 2018·Antimicrobial Agents and Chemotherapy·Laure StapertChris Pillar
Feb 7, 2019·The New England Journal of Medicine·William O'RiordanEvan Loh
Feb 7, 2019·The New England Journal of Medicine·Roman StetsEvan Loh
Citations
Aug 2, 2019·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jason C Gallagher
Nov 27, 2019·Antibiotics·Shao-Huan LanChien-Ming Chao
Jan 24, 2020·Drugs·George G ZhanelJames A Karlowsky
Sep 23, 2020·Future Microbiology·Teena ChopraGlenn Tillotson
Nov 13, 2020·European Journal of Drug Metabolism and Pharmacokinetics·Thomas L HuntPaul C McGovern
Jan 19, 2021·The Journal of Antimicrobial Chemotherapy·Manjunath P PaiPaul C McGovern
Nov 18, 2020·BMC Microbiology·Meng XiaoYing-Chun Xu
Oct 30, 2020·Pharmaceuticals·Nicola PrincipiSusanna Esposito
Sep 25, 2021·Pharmacotherapy·Monique R Bidell, Thomas P Lodise